先天性膈疝相关持续性肺动脉高压前列环素治疗的Meta分析
该系统评价与Meta分析纳入9项研究、共7009例婴儿,评估前列环素治疗先天性膈疝相关持续性肺动脉高压的疗效与安全性。Meta分析显示前列环素组氧合指数(OI)较对照组显著下降(MD 9.34,I² 0%,p<0.00001),但死亡率、ECMO使用、BNP、FiO2及室间隔曲率等结局均无统计学显著差异;应用Hartung-Knapp校正后除BNP外其他合并效应均不显著,证据质量多为极低。
要点
- 前列环素可能暂时改善氧合,OI较对照组显著下降(MD 9.34,p<0.00001)。
- 死亡率、ECMO使用、BNP、FiO2及室间隔曲率等结局均无显著差异。
- 多数结局证据质量极低,Hartung-Knapp校正后除BNP外合并效应均不显著。
核心结论
- 该Meta分析确认前列环素可能暂时改善氧合,但经Hartung-Knapp校正后除BNP外其他合并效应均无统计学显著性,仍需高质量研究验证。
研究设计与样本
- 系统检索PubMed、Web of Science、EMBASE和Cochrane CENTRAL四个数据库,方案预先在PROSPERO注册(CRD420261325458)。
- 共纳入9项研究、合计7009例婴儿进行系统评价与Meta分析。
- 采用GRADE评估证据质量,多数结局评为极低质量,仅一项评为中等质量。
主要发现
- 前列环素组氧合指数(OI)较对照组显著下降(MD 9.34,I² 0%,p<0.00001)。
- 死亡率无统计学显著差异(OR 0.83,I² 84%,p=0.70)。
- ECMO使用无统计学显著差异(OR 4.9,I² 98%,p=0.27)。
- BNP无统计学显著差异(std MD 6.98,I² 98%,p=0.31)。
- FiO2、室间隔收缩期曲率及舒张期室间隔差异均无统计学显著差异。
关键数值与推荐
- 氧合指数(OI):MD 9.34,I² 0%,p<0.00001(前列环素组 vs 对照组)。
- 死亡率:OR 0.83,I² 84%,p=0.70。
- ECMO:OR 4.9,I² 98%,p=0.27。
- BNP:std MD 6.98,I² 98%,p=0.31。
- FiO2:SMD 8.0,I² 64%,p=0.11;室间隔收缩期曲率SMD 0.69,I² 97%,p=0.32;舒张期室间隔差异MD 0.62,I² 93%,p=0.26。
临床怎么用
- 前列环素或可暂时改善先天性膈疝相关持续性肺动脉高压婴儿的氧合,但现有证据质量多为极低,不能据此确立常规疗效。
- 对死亡率、ECMO需求等硬结局的改善缺乏统计学支持,临床决策需结合个体情况并等待高质量研究。
局限性
- GRADE评估显示多数结局证据质量极低,仅一项为中等质量。
- ECMO和室间隔曲率等指标异质性高(I²分别达98%和97%)。
- 应用Hartung-Knapp校正后除BNP外其他合并效应均不显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
J Pediatr Surg. 2026 Oct;61(10):163301. doi: 10.1016/j.jpedsurg.2026.163301. Epub 2026 Jul 23. ABSTRACT OBJECTIVE: To evaluate the efficacy and safety of prostacyclin in the treatment of persistent pulmonary hypertension in congenital diaphragmatic hernia. METHODS: A systematic literature search was conducted in four main databases (PubMed, Web of Science, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The protocol was registered in advance in the International Prospective of Systematic Reviews (CRD420261325458). RESULTS: A total of nine studies were included involving a total of 7009 infants in this systematic review and meta-analysis. GRADE assessment revealed substantial heterogeneity in the quality of evidence across outcomes, with most outcomes rated very low quality and only one rated moderate quality. Studies were performed meta-analysis, which showed the use of prostacylin resulted a statistically significant decrease in the OI compared to the control group (Mean Difference (MD), 9.34; I 2 0%; p < 0.00001), no statistically significant in mortality (OR, 0.83; I 2 84%; p = 0.70), ECMO (OR = 4.9; I 2 98%; p = 0.27), BNP (std MD, 6.98; I 2 98%; p = 0.31), FiO2 (SMD = 8.0;, I 2 64%; p = 0.11), Systolic orientation of IVS curvature (SMD = 0.69; I 2 97%; p = 0.32), Diastolic orientation of IVS differences (MD = 0.62; I 2 93% p = 0.26). After applying the Hartung-Knapp adjustment, with the exception of BNP, the pooled effects of the other outcomes were not statistically significant, and there was high heterogeneity in measures such as ECMO and ventricular septal curvature. CONCLUSION: In conclusion, this meta-analysis has confirmed that prostacyclin may temporarily improve oxygenation. However, after applying the Hartung-Knapp adjustment, with the exception of BNP, the pooled effects of the other outcomes were not statistically significant, and there was high heterogeneity in measures such as ECMO and ventricular septal curvature. Further validation through high-quality studies are still needed. TRIAL REGISTRATION: PROSPERO: CRD420261325458. PMID: 42492725 | DOI: 10.1016/j.jpedsurg.2026.163301
引用
- PubMed 高证据 · 肺动脉高压:Meta-analysis of prostacyclin therapy for persistent pulmonary hypertension with congenital diaphragmatic hernia
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。